☰

Tibor Szarvas, Ph.D. - Publications

Affiliations: 
2008 Semmelweis Egyetem, Hungary 
Area:
Oncology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

91 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Tóth G, Sugár S, Pál D, Fügedi KD, Drahos L, Schlosser G, Oláh C, Reis H, Kovalszky I, Szarvas T, Turiák L. Glycosaminoglycan Analysis of FFPE Tissues from Prostate Cancer and Benign Prostate Hyperplasia Patients Reveals Altered Regulatory Functions and Independent Markers for Survival. Cancers. 14. PMID 36230789 DOI: 10.3390/cancers14194867  0.55
2020 Olah C, Tschirdewahn S, Hoffmann MJ, Krafft U, Hadaschik B, Nyirady P, Szendröi A, Módos O, Csizmarik A, Kovalszky I, Reis H, Szarvas T. Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients. Diagnostics (Basel, Switzerland). 10. PMID 33114033 DOI: 10.3390/diagnostics10110864  0.562
2020 Hollósi P, Váncza L, Karászi K, Dobos K, Péterfia B, Tátrai E, Tátrai P, Szarvas T, Paku S, Szilák L, Kovalszky I. Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1. Biomolecules. 10. PMID 32977498 DOI: 10.3390/biom10101356  0.717
2020 Hager T, Kraywinkel K, Szarvas T, Hadaschik B, Schmid KW, Reis H. Urachal Cancer in Germany and the USA: An RKI/SEER Population-Based Comparison Study. Urologia Internationalis. 104: 1-7. PMID 32784300 DOI: 10.1159/000509481  0.345
2020 Nagy N, Reis H, Hadaschik B, Niedworok C, Módos O, Szendrői A, Bíró K, Hager T, Herold T, Ablat J, Black PC, Okon K, Tolkach Y, Csizmarik A, Oláh C, ... ... Szarvas T, et al. Prevalence of APC and PTEN Alterations in Urachal Cancer. Pathology Oncology Research : Por. PMID 32754865 DOI: 10.1007/S12253-020-00872-6  0.603
2020 Niedworok C, Kempkensteffen C, Eisenhardt A, Tschirdewahn S, Rehme C, Panic A, Reis H, Baba H, Nyirády P, Hadaschik B, Kovalszky I, Szarvas T. Serum and tissue syndecan-1 levels in renal cell carcinoma. Translational Andrology and Urology. 9: 1167-1176. PMID 32676400 DOI: 10.21037/Tau-19-787  0.604
2020 Kovács PT, Juhász D, Módos O, Kocsmár I, Terebessy A, Lotz G, Szarvas T, Nyirády P, Riesz P. Characteristics of bladder recurrence after radical nephroureterectomy in upper urinary tract cancer Orvosi Hetilap. 161: 881-888. PMID 32427573 DOI: 10.1556/650.2020.31709  0.374
2020 Szarvas T, Csizmarik A, Nagy N, Keresztes D, Váradi M, Küronya Z, Riesz P, Nyirády P. Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer Orvosi Hetilap. 161: 813-820. PMID 32364360 DOI: 10.1556/650.2020.31734  0.322
2020 Szarvas T, Csizmarik A, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Püllen L, Jurányi Z, Kocsis Z, Shariat SF, Sevcenco S, Maj-Hes A, Kramer G. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. Bju International. PMID 32314509 DOI: 10.1111/Bju.15086  0.314
2020 Nini A, Hoffmann MJ, Lampignano R, Große Siemer R, van Dalum G, Szarvas T, Cotarelo CL, Schulz WA, Niederacher D, Neubauer H, Stoecklein NH, Niegisch G. Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. Cytometry. Part B, Clinical Cytometry. PMID 32212383 DOI: 10.1002/Cyto.B.21877  0.371
2020 Metzenmacher M, Váraljai R, Hegedüs B, Cima I, Forster J, Schramm A, Scheffler B, Horn PA, Klein CA, Szarvas T, Reis H, Bielefeld N, Roesch A, Aigner C, Kunzmann V, et al. Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. Cancers. 12. PMID 32033141 DOI: 10.3390/Cancers12020353  0.388
2020 Reis H, Szarvas T. [Predictive biomarkers in bladder cancer]. Der Pathologe. 40: 331-338. PMID 31705236 DOI: 10.1007/S00292-019-00688-5  0.405
2019 Szarvas T, Reis H. Editorial Comment from Dr Szarvas and Dr Reis to Clinicopathological features of malignant urachal tumor: A hospital-based cancer registry data in Japan. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 31803984 DOI: 10.1111/Iju.14164  0.331
2019 Reis H, Mairinger F, Ting S, Nagy N, Witzke KE, Kohl M, Sitek B, Niedworok C, Hadaschik B, Nyirády P, Szarvas T. [Urachal Cancer: an update of current molecular findings]. Der Pathologe. PMID 31705235 DOI: 10.1007/S00292-019-00689-4  0.4
2019 Szarvas T, Oláh C, Riesz P, Géczi L, Nyirády P. [Molecular subtype classification of urothelial bladder cancer and its clinical relevance]. Orvosi Hetilap. 160: 1647-1654. PMID 31608691 DOI: 10.1556/650.2019.31559  0.411
2019 Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik BA, Nyirády P, Szendröi A, Szücs M, Módos O, Olah C, Székely E, Reis H, Szarvas T. STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients. Pathology Oncology Research : Por. PMID 31250373 DOI: 10.1007/S12253-019-00689-Y  0.381
2019 Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik B, Olah C, Krege S, Nyirády P, Szendröi A, Szücs M, Módos O, Székely E, Reis H, Szarvas T. Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. Urologic Oncology. PMID 31053526 DOI: 10.1016/J.Urolonc.2019.04.015  0.351
2019 Szarvas T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, Nyirady P, Oláh C, Széll T, Csizmarik A, Hadaschik B, Reis H. High soluble CGA levels are associated with poor survival in bladder cancer. Endocrine Connections. PMID 30999279 DOI: 10.1530/Ec-19-0068  0.385
2019 Reis H, Szarvas T. Urachal cancer-current concepts of a rare cancer. Pathologe. 40: 31-39. PMID 30895340 DOI: 10.1007/S00292-018-0516-9  0.409
2019 Szarvas T, Csizmarik A, Szűcs M, Nyirády P. [Molecular subtypes and perspectives of targeted therapies in prostate cancer]. Orvosi Hetilap. 160: 252-263. PMID 30741006 DOI: 10.1556/650.2019.31315  0.389
2019 Küronya Z, Sükösd F, Varga L, Bíró K, Gyergyay F, Géczi L, Nagyiványi K, Jorgo K, Szarvas T, Kovács Á, Laczó I, Varga Z, Pósfai B, Pepó J, Maráz A. ERG expression can predict the outcome of docetaxel combinedwith androgen deprivation therapy in metastatic hormone-sensitiveprostate cancer. Urologic Oncology. PMID 30679082 DOI: 10.1016/J.Urolonc.2018.12.007  0.362
2019 Tschirdewahn S, Panic A, Püllen L, Harke NN, Hadaschik BH, Riesz P, Horváth A, Szalontai J, Nyirády P, Baba HA, Reis H, Szarvas T. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma. International Journal of Cancer. PMID 30650187 DOI: 10.1002/Ijc.32124  0.347
2019 Szarvas T, Olah C, Reis H. Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes? Translational Cancer Research. 8. DOI: 10.21037/26558  0.339
2019 Keresztes D, Módos O, Szűcs M, Hüttl A, Csizmarik A, Nagy N, Kretz V, Bracht T, Sitek B, Witzke K, Puhr M, Sevcenko S, Kramer G, Shariat S, Nyirády P, ... Szarvas T, et al. Comparative proteome analysis identified NAMPT as a potential serum marker for the prediction of docetaxel-resistance in prostate cancer European Urology Supplements. 18: e482. DOI: 10.1016/S1569-9056(19)30361-6  0.354
2018 Krafft U, Reis H, Ingenwerth M, Kovalszky I, Becker M, Niedworok C, Darr C, Nyirády P, Hadaschik B, Szarvas T. Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer. Pathology Oncology Research : Por. PMID 30019121 DOI: 10.1007/S12253-018-0447-Z  0.632
2018 Darr C, Krafft U, Hadaschik B, Tschirdewahn S, Sevcenco S, Csizmarik A, Nyirady P, Küronya Z, Reis H, Maj-Hes A, Shariat SF, Kramer G, Szarvas T. The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. Urologia Internationalis. 1-9. PMID 29949801 DOI: 10.1159/000489891  0.338
2018 Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Puhr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, Shariat SF, Kramer G. MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. Bju International. PMID 29802777 DOI: 10.1111/Bju.14415  0.335
2018 Reis H, Krafft U, Niedworok C, Módos O, Herold T, Behrendt M, Al-Ahmadie H, Hadaschik B, Nyirady P, Szarvas T. Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data. Disease Markers. 2018: 7308168. PMID 29721106 DOI: 10.1155/2018/7308168  0.406
2018 Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, ... ... Szarvas T, et al. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas. International Journal of Cancer. PMID 29672836 DOI: 10.1002/Ijc.31547  0.582
2018 Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Kubik A, Romics M, Kovalszky I, Reis H, Hadaschik B, Shariat SF, Kramer G. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. Urologic Oncology. PMID 29628317 DOI: 10.1016/J.Urolonc.2018.03.010  0.563
2018 Szarvas T, Nyirády P, Ogawa O, Furuya H, Rosser CJ, Kobayashi T. Erratum to: Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma. Methods in Molecular Biology (Clifton, N.J.). 1655: E1. PMID 29442339 DOI: 10.1007/978-1-4939-7234-0_25  0.335
2018 Szarvas T, Nyirády P, Kobayashi T, Ogawa O, Rosser CJ, Furuya H. Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma. Methods in Molecular Biology (Clifton, N.J.). 1655: 251-273. PMID 28889391 DOI: 10.1007/978-1-4939-7234-0_19  0.431
2018 Keresztes D, Bracht T, Sitek B, Witzke K, Puhr M, Miklós S, Módos O, Csizmarik A, Nagy N, Kramer G, Shariat S, Nyirády P, Szarvas T. Identification of predictive serum biomarkers for chemotherapy resistance in prostate cancer using mass spectrometric proteome analysis European Urology Supplements. 17: e2647. DOI: 10.1016/S1569-9056(18)33491-2  0.343
2017 Thiem S, Herold T, Krafft U, Bremmer F, Tolkach Y, Szász AM, Kriegsmann J, Gaisa NT, Niedworok C, Szarvas T, Reis H. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer. Pathology International. PMID 29047227 DOI: 10.1111/Pin.12594  0.327
2017 Droop J, Szarvas T, Schulz WA, Niedworok C, Niegisch G, Scheckenbach K, Hoffmann MJ. Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma. Plos One. 12: e0176287. PMID 28430799 DOI: 10.1371/Journal.Pone.0176287  0.347
2017 Modos O, Keresztes D, Nyirády P, Szendröi A, Tímár J, Szász A, Reis H, Niedworok C, Hadaschik B, Hollósi P, Baghy K, Kovalszky I, Okon K, Golabek T, Chlosta P, ... ... Szarvas T, et al. Molecular and therapeutic aspects of advanced urachal cancer European Urology Supplements. 16: e2840. DOI: 10.1016/S1569-9056(17)31982-6  0.591
2016 Niedworok C, Tschirdewahn S, Reis H, Lehmann N, Szücs M, Nyirády P, Romics I, Rübben H, Szarvas T. Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival. Pathology Oncology Research : Por. PMID 28012116 DOI: 10.1007/S12253-016-0171-5  0.366
2016 Szarvas T, Módos O, Horváth A, Nyirády P. Why are upper tract urothelial carcinoma two different diseases? Translational Andrology and Urology. 5: 636-647. PMID 27785420 DOI: 10.21037/Tau.2016.03.23  0.309
2016 Fullár A, Firneisz G, Regős E, Dudás J, Szarvas T, Baghy K, Ramadori G, Kovalszky I. Response of Hepatic Stellate Cells to TGFB1 Differs from the Response of Myofibroblasts. Decorin Protects against the Action of Growth Factor. Pathology Oncology Research : Por. PMID 27495255 DOI: 10.1007/S12253-016-0095-0  0.512
2016 Nyirády P, Niedworok C, Reis H, Szarvas T. Clinical Sequencing-guided Therapy of Urachal Carcinoma: New Perspective for a Rare Cancer. European Urology. PMID 27423504 DOI: 10.1016/J.Eururo.2016.07.004  0.418
2016 Módos O, Reis H, Niedworok C, Rübben H, Szendröi A, Szász MA, Tímár J, Baghy K, Kovalszky I, Golabek T, Chlosta P, Okon K, Peyronnet B, Mathieu R, Shariat SF, ... ... Szarvas T, et al. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma - occurence and prognostic significance. Oncotarget. PMID 27283768 DOI: 10.18632/Oncotarget.9828  0.752
2016 Szarvas T, Módos O, Niedworok C, Reis H, Szendröi A, Szász MA, Nyirády P. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases. Urologic Oncology. PMID 27267737 DOI: 10.1016/J.Urolonc.2016.04.012  0.306
2016 Szarvas T, Reis H, Vom Dorp F, Tschirdewahn S, Niedworok C, Nyirady P, Schmid KW, Rübben H, Kovalszky I. Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer. The Prostate. 76: 977-85. PMID 27062540 DOI: 10.1002/Pros.23186  0.61
2016 Niedworok C, Vom Dorp F, Tschirdewahn S, Rübben H, Reis H, Szucs M, Szarvas T. Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method. International Urology and Nephrology. 48: 355-61. PMID 26725072 DOI: 10.1007/S11255-015-1185-8  0.384
2016 Niedworok C, Panitz M, Szarvas T, Reis H, Reis AC, Szendröi A, Nyirády P, Szasz AM, Módos O, Rübben H, Vom Dorp F. Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis. The Journal of Urology. 195: 1690-6. PMID 26678957 DOI: 10.1016/J.Juro.2015.11.067  0.373
2015 Hoffmann MJ, Dehn J, Droop J, Niegisch G, Niedworok C, Szarvas T, Schulz WA. Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors. Non-Coding Rna. 1: 266-284. PMID 29861427 DOI: 10.3390/Ncrna1030266  0.382
2015 Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T. Circulating and tissue expression levels of YKL-40 in renal cell cancer. The Journal of Urology. PMID 26454102 DOI: 10.1016/J.Juro.2015.09.084  0.402
2015 Acs B, Szarvas T, Szekely N, Nyirady P, Szasz AM. Current State of ERG as Biomarker in Prostatic Adenocarcinoma. Current Cancer Drug Targets. 15: 643-51. PMID 26452381 DOI: 10.2174/156800961508151001100829  0.374
2015 Heubach J, Monsior J, Deenen R, Niegisch G, Szarvas T, Niedworok C, Schulz WA, Hoffmann MJ. The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells. Molecular Cancer. 14: 108. PMID 25994132 DOI: 10.1186/S12943-015-0371-8  0.372
2015 Modos O, Szarvas T, Reis H, Niedworok C, Rübben H, Szendröi A, Szasz A, Hollosi P, Baghy K, Kovalszky I, Okon K, Golabek T, Chlosta P, Shariat S, Peyronnet B, et al. Mutation analysis of EGFR signal transduction pathway in urachal carcinoma European Urology Supplements. 14: e1215. DOI: 10.1016/S1569-9056(15)30251-7  0.531
2014 Sevcenco S, Haitel A, Ponhold L, Susani M, Fajkovic H, Shariat SF, Hiess M, Spick C, Szarvas T, Baltzer PA. Quantitative apparent diffusion coefficient measurements obtained by 3-Tesla MRI are correlated with biomarkers of bladder cancer proliferative activity. Plos One. 9: e106866. PMID 25202965 DOI: 10.1371/Journal.Pone.0106866  0.348
2014 Sevcenco S, Ponhold L, Heinz-Peer G, Fajkovic H, Haitel A, Susani M, Shariat SF, Szarvas T, Baltzer PA. Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. Urologic Oncology. 32: 1166-71. PMID 24962659 DOI: 10.1016/J.Urolonc.2014.04.019  0.313
2014 Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, et al. External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1804-12. PMID 24920641 DOI: 10.1158/1055-9965.Epi-14-0029  0.388
2014 Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendröi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rübben H, Szarvas T. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urologic Oncology. 32: 663-9. PMID 24814404 DOI: 10.1016/J.Urolonc.2014.02.004  0.406
2014 Szarvas T, Reis H, Kramer G, Shariat SF, Vom Dorp F, Tschirdewahn S, Schmid KW, Kovalszky I, Rübben H. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. Human Pathology. 45: 674-82. PMID 24656090 DOI: 10.1016/J.Humpath.2013.10.036  0.607
2014 Szarvas T. Editorial comment from Dr Szarvas to Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: a mini-review. International Journal of Urology : Official Journal of the Japanese Urological Association. 21: 753. PMID 24635598 DOI: 10.1111/Iju.12440  0.331
2014 Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, Shariat SF, Rübben H, vom Dorp F. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. International Journal of Cancer. Journal International Du Cancer. 135: 1596-604. PMID 24615121 DOI: 10.1002/Ijc.28808  0.39
2014 Jäger T, Tschirdewahn S, Vom Dorp F, Piechotta G, Rübben H, Szarvas T. [Siliconchiptechnology-based MMP-7 analysis in urine: an option for preoperative identification of lymph node metastasis in bladder cancer]. Der Urologe. Ausg. A. 52: 853-8. PMID 23358831 DOI: 10.1007/S00120-012-3110-4  0.352
2014 Szarvas T, Sevcenco S, Shariat S, Kramer G. 106 Serum MMP-7, sFas and FasL levels in predicting therapy resistance and survival in castration-resistant prostate cancer patients treated with docetaxel European Urology Supplements. 13: e106. DOI: 10.1016/S1569-9056(14)60107-X  0.343
2014 Palacios DA, Chen L, Chang M, Dai Y, Andersen LD, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Jeronimo C, Parker AS, Ross S, Chai KX, Goodison S, Rosser CJ. Mp22-04 External Validation Of A Multiplex Urinary Protein Panel For The Detection Of Bladder Cancer In A Multicenter Cohort The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.852  0.393
2013 Niedworok C, Roc̈k K, Kretschmer I, Freudenberger T, Nagy N, Szarvas T, Vom Dorp F, Reis H, Rub̈ben H, Fischer JW. Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer Plos One. 8. PMID 24223213 DOI: 10.1371/Journal.Pone.0080084  0.446
2013 Niedworok C, Kretschmer I, Röck K, Vom Dorp F, Szarvas T, Heß J, Freudenberger T, Melchior-Becker A, Rübben H, Fischer JW. The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder. Plos One. 8: e75681. PMID 24069434 DOI: 10.1371/Journal.Pone.0075681  0.401
2013 Szarvas T. Editorial comment to characterization and risk stratification of prostate cancer in patients undergoing radical cystoprostatectomy. International Journal of Urology : Official Journal of the Japanese Urological Association. 20: 872. PMID 23379970 DOI: 10.1111/Iju.12088  0.335
2013 Niedworok C, Kretschmer I, Vom Dorp F, Szarvas T, Heß J, Freudenberger T, Melchior-Becker A, Fischer J, Rübben H. 155 The expression of the receptor of hyaluronan mediated motility (RHAMM) is associated with reduced disease-specific survival in patients with bladder cancer European Urology Supplements. 12: e155. DOI: 10.1016/S1569-9056(13)60644-2  0.362
2012 Szarvas T, Jäger T, Laszlo V, Kramer G, Klingler HC, vom Dorp F, Romics I, Ergün S, Rübben H. Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer. Urology. 80: 737.e13-8. PMID 22607948 DOI: 10.1016/J.Urology.2012.03.023  0.387
2012 Szarvas T, vom Dorp F, Niedworok C, Melchior-Becker A, Fischer JW, Singer BB, Reis H, Bánkfalvi Á, Schmid KW, Romics I, Ergün S, Rübben H. High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer. Bju International. 110: E308-17. PMID 22500655 DOI: 10.1111/J.1464-410X.2012.11149.X  0.368
2012 Szarvas T, László V, Vom Dorp F, Reis H, Szendröi A, Romics I, Tilki D, Rübben H, Ergün S. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer. International Journal of Cancer. 130: 2922-9. PMID 21815140 DOI: 10.1002/Ijc.26343  0.419
2012 Szarvas T, Kramer G, Hess J, Tschirdewahn S, Reis H, Romics I, Sevcenco S, Tötsch M, Rübben H, vom Dorp F. 1416 TISSUE MMP-7 EXPRESSION PREDICTS SURVIVAL IN BLADDER CANCER PATIENTS TREATED WITH CISPLATIN-BASED CHEMOTHERAPY Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1867  0.365
2011 Reis H, Tschirdewahn S, Szarvas T, Rübben H, Schmid KW, Grabellus F. Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder. Oncology Letters. 2: 1149-1153. PMID 22848280 DOI: 10.3892/Ol.2011.394  0.347
2011 Szarvas T, vom Dorp F, Ergün S, Rübben H. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nature Reviews. Urology. 8: 241-54. PMID 21487384 DOI: 10.1038/Nrurol.2011.44  0.338
2011 Hess J, Tschirdewahn S, Szarvas T, Rossi R, Rübben H, Vom Dorp F. [Urothelial carcinoma of the bladder: evaluation by combined endoscopy and urine cytology: is incontrovertible assessment possible?]. Der Urologe. Ausg. A. 50: 702-5. PMID 21465088 DOI: 10.1007/S00120-010-2502-6  0.343
2011 Szarvas T, Jäger T, Becker M, Tschirdewahn S, Niedworok C, Kovalszky I, Rübben H, Ergün S, vom Dorp F. Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathology Oncology Research : Por. 17: 325-32. PMID 21253919 DOI: 10.1007/S12253-010-9320-4  0.586
2011 Vom Dorp F, Pal P, Tschirdewahn S, Rossi R, Börgermann C, Schenck M, Becker M, Szarvas T, Hakenberg OW, Rübben H. Correlation of pathological and cytological-cytometric grading of transitional cell carcinoma of the urinary tract. Urologia Internationalis. 86: 36-40. PMID 21160157 DOI: 10.1159/000321017  0.397
2011 Szarvas T, Hoffmann F, Becker M, Schenck M, Vom Dorp F, Rübben H, Jäger T. [Plasma E-cadherin levels in urinary bladder cancer: does it improve risk stratification?]. Der Urologe. Ausg. A. 50: 64-70. PMID 21153394 DOI: 10.1007/S00120-010-2454-X  0.421
2011 Szarvas T, Singer BB, Becker M, Vom Dorp F, Jäger T, Szendroi A, Riesz P, Romics I, Rübben H, Ergün S. Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. Bju International. 107: 1069-73. PMID 20825402 DOI: 10.1111/J.1464-410X.2010.09625.X  0.358
2011 Szarvas T, Becker M, Vom Dorp F, Meschede J, Scherag A, Bánkfalvi A, Reis H, Schmid KW, Romics I, Rübben H, Ergün S. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. International Journal of Cancer. Journal International Du Cancer. 128: 1486-92. PMID 20473942 DOI: 10.1002/Ijc.25454  0.393
2010 Becker M, Szarvas T, Wittschier M, vom Dorp F, Tötsch M, Schmid KW, Rübben H, Ergün S. Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer. Cancer. 116: 4502-12. PMID 20564745 DOI: 10.1002/Cncr.25326  0.409
2010 Jäger T, Becker M, Eisenhardt A, Tilki D, Tötsch M, Schmid KW, Romics I, Rübben H, Ergün S, Szarvas T. The prognostic value of cadherin switch in bladder cancer. Oncology Reports. 23: 1125-32. PMID 20204300 DOI: 10.3892/Or_00000741  0.427
2010 Szarvas T, Becker M, vom Dorp F, Gethmann C, Tötsch M, Bánkfalvi A, Schmid KW, Romics I, Rübben H, Ergün S. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Science. 101: 1300-8. PMID 20180812 DOI: 10.1111/J.1349-7006.2010.01506.X  0.357
2009 Szarvas T. [The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer]. Magyar Onkologia. 53: 385-9. PMID 20071311 DOI: 10.1556/Monkol.53.2009.4.8  0.477
2009 Niedworok C, Rembrink V, Hakenberg OW, Börgermann C, Rossi R, Schneider T, Becker M, Szarvas T, von Ostau C, Swoboda A, Rübben H, vom Dorp F. [The value of urinary cytology in the diagnosis of high grade urothelial tumors]. Der Urologe. Ausg. A. 48: 1018, 1020-2, 1024. PMID 19697005 DOI: 10.1007/S00120-009-2077-2  0.349
2009 Tschirdewahn S, Boergermann C, Becker M, Szarvas T, Rübben H, vom Dorp F. [Urine-based cytological diagnosis against the background of the new histopathological classification]. Der Urologe. Ausg. A. 48: 615-8. PMID 19557466 DOI: 10.1007/S00120-009-1990-8  0.343
2009 Szarvas T, Jäger T, Droste F, Becker M, Kovalszky I, Romics I, Ergün S, Rübben H. Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathology Oncology Research : Por. 15: 193-201. PMID 18807212 DOI: 10.1007/S12253-008-9107-Z  0.618
2008 Szarvas T, Jäger T, Tötsch M, vom Dorp F, Kempkensteffen C, Kovalszky I, Romics I, Ergün S, Rübben H. Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 8253-62. PMID 19088043 DOI: 10.1158/1078-0432.Ccr-08-0677  0.579
2008 Jäger T, Szarvas T, vom Dorp F, Börgermann C, Schenck M, Schmid KW, Rübben H. [Use of silicon chip technology to detect protein-based tumor markers in bladder cancer]. Der Urologe. Ausg. A. 46: 1152-6. PMID 17593336 DOI: 10.1007/S00120-007-1429-Z  0.397
2007 Riesz P, Lotz G, Páska C, Szendrôi A, Majoros A, Németh Z, Törzsök P, Szarvas T, Kovalszky I, Schaff Z, Romics I, Kiss A. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathology Oncology Research : Por. 13: 187-94. PMID 17922047 DOI: 10.1007/Bf02893498  0.603
2007 Szarvas T, Kovalszky I, Bedi K, Szendroi A, Majoros A, Riesz P, Füle T, László V, Kiss A, Romics I. Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. Oncology Reports. 18: 405-9. PMID 17611663  0.774
2007 Szarvas T, Kovalszky I, Bedi K, Szendroi A, Majoros A, Riesz P, Füle T, László V, Kiss A, Romics I. Deletion analysis of tumor and urinary DNA to detect bladder cancer: Urine supernatant versus urine sediment Oncology Reports. 18: 405-409. DOI: 10.3892/Or.18.2.405  0.773
2006 Füle T, Máthé M, Suba Z, Csapó Z, Szarvas T, Tátrai P, Paku S, Kovalszky I. The presence of human papillomavirus 16 in neural structures and vascular endothelial cells. Virology. 348: 289-96. PMID 16499942 DOI: 10.1016/J.Virol.2005.12.043  0.704
2006 Firneisz G, Dudás J, Szarvas T, Sári E, Ramadori G, Kovalszky I. Different transforming growth factor-B1 induces extracellular matrix production in rat hepatic stellate cells versus hepatic myofibroblasts, but decorin inhibits both Zeitschrift FüR Gastroenterologie. 44. DOI: 10.1055/s-2006-943392  0.451
2005 Firneisz G, Dudás J, Saile B, Szarvas T, Lengyel G, Tulassay Z, Fehér J, Kovalszky I, Ramadori G. TGFB1 and decorin induced extracellular matrix protein production of hepatic stellate cells and myofibroblasts Zeitschrift FüR Gastroenterologie. 43. DOI: 10.1055/S-2005-869673  0.458
Show low-probability matches.